These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 8055815

  • 1. The efficacy, tolerability and safety of Parlodel LAR versus Parlodel in hyperprolactinemia.
    Bolanowski M, Milewicz A, Bohdanowicz-Pawlak A, Bednarek-Tupikowska G, Jedrzejak JA, Lancranjan I.
    Endokrynol Pol; 1993; 44(4):467-76. PubMed ID: 8055815
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
    Zgliczyński W, Zgliczyński S, Makowska A, Słowinska-Srzednicka J, Janik J, Jeske W, Walecki J.
    Endokrynol Pol; 1992; 43(3):234-41. PubMed ID: 1345564
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
    Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A.
    Fertil Steril; 1989 Dec; 52(6):930-5. PubMed ID: 2591571
    [Abstract] [Full Text] [Related]

  • 5. Tolerability, safety and efficacy of two formulations of Parlodel--a slow release oral form (SRO) versus registered Parlodel capsules.
    Biberoğlu K, Atasü T, Shabgahi B, Kandemir O.
    Gynecol Obstet Invest; 1994 Dec; 37(1):6-9. PubMed ID: 8125413
    [Abstract] [Full Text] [Related]

  • 6. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B, Colao A, Caruso E, Sarnacchiaro F, Briganti F, Lancranjan I, Lombardi G, Schettini G.
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [Abstract] [Full Text] [Related]

  • 7. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.
    Pagani MD, Tengattini F, Montini M, Pagani G, Pedroncelli A, Gianola D, Gherardi F, Mazzocchi N, Cortesi L, Lancranjan I.
    Clin Endocrinol (Oxf); 1992 Apr; 36(4):369-74. PubMed ID: 1424170
    [Abstract] [Full Text] [Related]

  • 9. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
    Gianola D, Pedroncelli A, Montini M, Tengattini F, Pagani MD, Cortesi L, Cappi MP, Gherardi F, Lancranjan I, Pagani G.
    Gynecol Endocrinol; 1991 Sep; 5(3):213-6. PubMed ID: 1776507
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of a long-acting intramuscularly injectable depot preparation of bromocriptine: the results of a double blind study.
    Schulz A, Lancranjan I, Schürmeyer T, Schuppert F, Hesch RD, von zur Mühlen A, Brabant G.
    J Endocrinol Invest; 1991 Jun; 14(6):469-74. PubMed ID: 1774443
    [Abstract] [Full Text] [Related]

  • 11. [Parenteral, depot and repeatable forms of Parlodel LAR bromocriptine in the treatment of hyperprolactinemia syndrome. Comparison with oral Parlodel].
    Dolecek R, Lancranjanová I, Putz Z, Vavros D, Závada M.
    Cas Lek Cesk; 1993 Feb 15; 132(3):81-5. PubMed ID: 8458069
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. New perspectives in medical management of hyperprolactinemia.
    Montini M, Gianola D, Pagani MD, Tengattini F, Dominoni P, Sileo F, Ferrari L, Stroppa S, Gualteroni L, Pagani G.
    Endocrinol Exp; 1990 Mar 15; 24(1-2):159-66. PubMed ID: 2361458
    [Abstract] [Full Text] [Related]

  • 15. Mixed pituitary tumours--effects of bromocriptine treatment: Parlodel MR and Parlodel LAR.
    Zgliczyński W, Zgliczyński S, Makowska A, Słowinska-Srzednicka J, Janik J, Jeske W, Walecki J.
    Endokrynol Pol; 1992 Mar 15; 43(3):242-9. PubMed ID: 1345565
    [Abstract] [Full Text] [Related]

  • 16. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
    Lengyel AM, Mussio W, Imamura P, Vieira JG, Lancranjan I.
    Fertil Steril; 1993 May 15; 59(5):980-7. PubMed ID: 8486199
    [Abstract] [Full Text] [Related]

  • 17. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
    Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP.
    J Endocrinol Invest; 1996 May 15; 19(7):472-9. PubMed ID: 8884542
    [Abstract] [Full Text] [Related]

  • 18. The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study.
    van der Heijden PF, Lappöhn RE, Corbey RS, de Goeij WB, Brownell J, Rolland R.
    Fertil Steril; 1989 Oct 15; 52(4):574-9. PubMed ID: 2806597
    [Abstract] [Full Text] [Related]

  • 19. Immunoreactive prolactin in breast milk and plasma of women with hyperprolactinemia, galactorrhea and menstrual dysfunction.
    Yuen BH.
    Int J Fertil; 1986 Oct 15; 31(1):67-70. PubMed ID: 2908279
    [Abstract] [Full Text] [Related]

  • 20. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I.
    Clin Endocrinol (Oxf); 1990 Aug 15; 33(2):161-9. PubMed ID: 2225475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.